Outlook Therapeutics, Inc.

NASDAQ:OTLK

Biotechnology

Healthcare
$0.41 -5.76%

-$0.10 today

Market cap
$99.30M
Beta
0.98
P/E (TTM)
-2.1
EPS (TTM)
-$0.74
52W Low $0.16High $3.39

Volume 4.42M

Average 17.46M

OTLK Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Outlook Therapeutics, Inc.NASDAQ: OTLK

Operating Expenses · Q2 FY2026 · quarter ended Mar 2026

Operating expenses growth accelerates

Q2 FY2026 operating expenses of $14.01M rose 13.0% year over year, ahead of the -22.3% change in trailing-twelve-month operating expenses. Sequentially, it rose 14.4% from the prior quarter. Over 3 fiscal years it compounded at +2.5% a year.

Context

  • Operating expenses amounted to 4790.7% of revenue in FY2025.
  • Operating expenses increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +13.0% holds above the trailing-twelve-month pace of -22.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$14.01M+14.4% QoQ
Last fiscal yearSep 2025
$67.72M-5.6% YoY
LTMMar 2026
$59.37M-22.3% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+13.0%——
1 year-5.6%——
3-year CAGR+2.5%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
67.72M USD
Year-over-year change
-5.6%
4-year CAGR
+7.0%

Operating Expenses vs competitors

How OTLK compares with its peers on the latest reported figures

  • OTLK's LTM Mar 2026 operating expenses of $59.37M is the 2nd highest of the 9 companies compared; the peer median is $33.76M.
  • Its year-over-year change of -22.3% is the 5th highest of 9, against a peer median of -18.3%.
  • Operating expenses amounts to 17821.9% of revenue for OTLK, versus a peer median of 497.5%.
OTLK Competitors Peer median
Operating Expenses for OTLK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IPSCCentury Therapeutics, Inc.LTM Mar 2026$87.08M -41.0%-7.2%—
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$59.37M -22.3%+2.5%17821.9%
CUECue Biopharma, Inc.LTM Mar 2026$52.24M +6.3%-0.3%159.6%
HOWLWerewolf Therapeutics, Inc.LTM Jun 2026$43.72M -39.4%-5.5%208.2%
SPRBSpruce Biosciences, Inc.LTM Mar 2026$34.01M -44.2%-8.3%—
OSTXOS Therapies IncorporatedLTM Mar 2026$33.51M +199.7%+85.4%—
EQEquillium, Inc.LTM Mar 2026$20.3M -54.6%-32.8%—
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$18.04M +2.8%-27.4%786.8%
COEPCoeptis Therapeutics, Inc.LTM Mar 2026$14.13M +26.1%-25.3%999.7%
Peer median (excluding OTLK) $33.76M-18.3%-7.7%497.5%

Competitors are the stored peer set for OTLK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue00001.41M
Cost of Revenue262.14K204.69K44.19K113.86K756.33K
Gross Profit(262.14K)(204.69K)(44.19K)(113.86K)657.21K
Gross Margin————46.5%
Research & Development38.96M42.33M26.45M41.76M27.18T
Selling, General & Admin12.77M20.74M26.67M29.94M39.94M
Operating Expenses51.73M62.87M53.13M71.7M67.72M
Depreciation & Amortization262.14K204.69K44.19K113.86K117.05K
EBITDA(51.51M)(64.36M)(57.38M)(72.09M)(63.58M)
EBITDA Margin————-4497.7%
Operating Income(51.73M)(63.07M)(53.13M)(71.7M)(67.06M)
Operating Margin————-4744.3%
Interest Income000906.15K89.74K
Interest Expense936.13K1.49M1.56M3.16M283.13K
Other Income / Expenses(1.43M)(2.98M)(5.85M)(3.66M)3.08M
Income Before Tax(53.16M)(66.05M)(58.98M)(75.36M)(63.98M)
Pre-Tax Margin————-4526.0%
Income Tax Expense2K2.8K2.8K2.8K(1.55M)
Net Income(53.16M)(66.05M)(58.98M)(75.37M)(62.42M)
Net Margin————-4416.2%
EPS (Basic)(6.96)(6.23)(4.72)(4.06)(1.79)
EPS (Diluted)(6.96)(6.23)(4.72)(4.06)(1.79)
Weighted Avg Shares7.63M10.6M12.51M18.55M34.8M
Weighted Avg Shares (Diluted)7.63M10.6M12.51M18.55M25.48M

Outlook Therapeutics, Inc.

NASDAQ:OTLK

Intrinsic Alpha fair value

Locked

Current Price

$0.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.